Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06779097 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

Name: Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis — clinical trial record (NCT06779097)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.

Started2025-02

View on ClinicalTrials.gov ↗

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

75 trials monitored

See 7 trials at risk

Psoriasis

418 trials monitored

See 17 trials at risk

This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis who have converted from other biologics. To explore the efficacy of difficult-to-treat area, patient satisfaction and patient-reported outcomes (PRO).

Trial Details

NCT Number	NCT06779097
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Moderate to Severe Plaque Psoriasis
Enrollment	1,564 participants
Start Date	2025-02
Primary Completion	2027-03 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2025-01-16